X-ZELL facing three start-up competition finals in one week

Singapore, November 2020 – Singapore start-up X-ZELL has been nominated for the finals of three high-profile start-up competitions and accelerator programs, all taking place within the same week from 11-18 Nov 2020.

World’s Most Innovative Health Tech Start-up

Organised by global analyst firm, Galen Growth, the annual competition is pitting the world’s 64 most promising digital health start-ups against each other in a knock-out system.

According to Galen Growth – which can draw on a 6,300 company strong digital health database called HealthTech Alpha – the selection was made based on partnerships, coverage, clinical approvals and funding performance in 2019-20.

X-ZELL – a member of the 2020 Galen Growth Cohort – entered the competition as one of five “wildcard entries” nominated by popular vote.

The final round is now open for voting and will close on 11 November (time TBA) – coinciding with the official start of Galen Growth’s Global HealthTech Summit. Vote here: https://bit.ly/2HSKZQn

The Grand Final will then take place at the end of the three-day virtual conference on 13 Nov at 7:50 pm SGT. Secure a spot here: https://bit.ly/385vDCV

Hello Tomorrow Global Challenge

Only three days after the long-anticipated Galen Growth Summit, X-ZELL will compete at the Hello Tomorrow Global Challenge.

Considered one of the leading deep tech start-up competitions in the world, it was created to celebrate the “best and brightest breakthrough solutions” made possible by science and technology and is part of the annual Hello Tomorrow Summit.

According to Hello Tomorrow’s organising committee, it received a record-breaking 5,000 applications from 128 countries for the 2020 instalment, with X-ZELL being one of five finalists in the ‘Medical Biotech’ category. 

After being postponed due to the Covid-19 pandemic, the event has now gone virtual and will take place between 16-20 Nov.

X-ZELL will be pitching on Day One of the Summit, with the full agenda yet to be confirmed. Secure a ticket here and make sure to vote for X-ZELL on the day: https://bit.ly/35Upjvw 

MedTech Innovator Asia Pacific Competition

On 18 November, X-ZELL will be one of five finalists to compete at the 2020 MedTech Innovator Asia Pacific Competition.

The Grand Final will complete a journey that began in July 2020 with X-ZELL’s selection for MedTech Innovator’s 2020 Asia Pacific Accelerator program – the largest accelerator of medical devices in the world.

Organised in partnership with the Asia Pacific Medical Technology Association (APACMed) and sponsored by Johnson & Johnson Medical Devices, the program was designed to support the region’s “best and brightest” on the road to bringing innovative ideas to market.

The final round will be broadcast online. Secure a ticket here: https://bit.ly/3kUE5IK

Media Contact:
Sebastian Grote
Head of Strategy, Marketing & Communications
+65 9630 0706
sebastian.g@x-zell.com
www.x-zell.com

About X-ZELL
X-ZELL’s vision is to save lives by identifying clinically significant cancers early, when there is still time to act and take charge of our health. X-ZELL first made headlines in 2017 when it found a way to routinely locate tumour-associated Circulating Endothelial Cells (tCEC) in a small, 10mL blood sample.  Known to be powerful biomarkers for the early detection of aggressive cancers, tCEC were long considered ‘undetectable’ in clinical routine. X-ZELL overcame the impasse by developing a platform technology that is capable of detecting a single tCEC among five billion healthy blood cells and analysing it using Artificial Intelligence – making for an affordable, non-invasive solution with maximum scalability. Less than a year after that breakthrough, X-ZELL was able to present the world’s first tCEC-based blood test for the early detection of clinically significant prostate cancer – X-ZELL™ Prostate. But one cancer is not enough. X-ZELL’s ambition is to make accurate, affordable tCEC screening available to everyone, everywhere – which is why additional tests for common cancers such as breast, ovarian, colon and lung have already gone into pre-development, with more to come. They all feed into the creation of an AI-driven general screening test that will be able to scrutinise our blood for atypical cells and analyse them on-screen – allowing physicians to manage our health proactively instead of just responding to a disease.